• 01 DEC 15
    • 0
    Νέα θεραπεία του πολλαπλού μυελώματος με ένα στοχευμένο ανοσοενισχυτικό βιολογικό παράγοντα

    Νέα θεραπεία του πολλαπλού μυελώματος με ένα στοχευμένο ανοσοενισχυτικό βιολογικό παράγοντα

    Η επιτροπή φαρμάκων και τροφίμων στις ΗΠΑ (FDA) ενέκρινε ένα νέο ανοσοενισχυτικό φάρμακο για την θεραπεία του πολλαπλού μυελώματος: Empliciti (elotuzumab). Είναι ένα μονοκλωνικό αντίσωμα που δρα σε συνέργεια με το Darzalex (άλλο αντίσωμα) για να προσφέρει ισχυρή ανοσολογική επίθεση και να σκοτώσει τα κακοήθη κύτταρα.

    Μultiple myeloma is a form of blood cancer that occurs in infection-fighting plasma cells (a type of white blood cell) found in the bone marrow. These cancerous cells multiply, produce an abnormal protein and push out other healthy blood cells from the bone marrow. This disease may result in a weakened immune system, and cause other bone and kidney problems. The National Cancer Institute estimates there will be 26,850 new cases of multiple myeloma and 11,240 related deaths in the United States this year.

    “We are continuing to learn about the ways the immune system interacts with different types of cancer, including multiple myeloma,» said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Today’s approval is the second monoclonal antibody approved to treat patients with multiple myeloma and works with another approved therapy to provide additional benefit.» Darzalex (daratumumab), approved earlier this month, is the only other FDA-approved monoclonal antibody for the treatment of patients with multiple myeloma.

    Empliciti activates the body’s immune system to attack and kill multiple myeloma cells. It is approved in combination with another FDA-approved treatment for multiple myeloma called Revlimid (lenalidomide) and dexamethasone (a type of corticosteroid).

    The safety and efficacy of Empliciti were tested in a randomized, open-label clinical study of 646 participants whose multiple myeloma came back after, or did not respond to previous treatment. Those taking Empliciti plus Revlimid and dexamethasone experienced a delay in the amount of time before their disease worsened (19.4 months) compared to participants taking only Revlimid and dexamethasone (14.9 months). Additionally, 78.5 percent of those taking Empliciti with Revlimid and dexamethasone saw a complete or partial shrinkage of their tumors compared to 65.5 percent in those only taking Revlimid and dexamethasone.

    The most common side effects of Empliciti are fatigue, diarrhea, fever (pyrexia), constipation, cough, nerve damage resulting in weakness or numbness in the hands and feet (peripheral neuropathy), infection of the nose and throat (nasopharyngitis), upper respiratory tract infection, decreased appetite and pneumonia.

    Leave a reply →
Font Resize
visa mastercard